Telix Pharmaceuticals (NASDAQ:TLX) Stock Price Up 5.5% – Time to Buy?

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s stock price was up 5.5% during mid-day trading on Friday . The company traded as high as $7.52 and last traded at $7.52. Approximately 116,986 shares traded hands during mid-day trading, a decline of 51% from the average daily volume of 239,849 shares. The stock had previously closed at $7.13.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Wall Street Zen downgraded shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Citigroup raised their target price on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.13.

Telix Pharmaceuticals Price Performance

The firm’s 50 day moving average price is $7.32 and its two-hundred day moving average price is $8.99. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Telix Pharmaceuticals (NASDAQ:TLX) last released its quarterly earnings data on Thursday, February 19th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The company had revenue of $414.02 million during the quarter, compared to analysts’ expectations of $421.50 million. As a group, equities analysts forecast that Telix Pharmaceuticals Limited will post 0.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of TLX. Vident Advisory LLC acquired a new stake in shares of Telix Pharmaceuticals during the fourth quarter valued at about $204,000. XTX Topco Ltd purchased a new position in shares of Telix Pharmaceuticals during the 4th quarter worth approximately $89,000. Quadrature Capital Ltd acquired a new stake in Telix Pharmaceuticals in the 4th quarter valued at approximately $276,000. OLD Mission Capital LLC purchased a new stake in Telix Pharmaceuticals in the fourth quarter valued at approximately $111,000. Finally, Lazard Asset Management LLC lifted its stake in Telix Pharmaceuticals by 118.6% during the fourth quarter. Lazard Asset Management LLC now owns 250,517 shares of the company’s stock worth $1,876,000 after purchasing an additional 135,893 shares in the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.